Goldman Sachs analyst Matthew Sykes assumes coverage on Adeptus Biotechnologies Corp. (NASDAQ: ADPT) with a Neutral rating and a price ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE